Voyager Therapeutics Inc VYGR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
-
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
-
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
-
Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
-
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
-
Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Shares Leap Premarket on Novartis Collaboration
Trading Information
- Previous Close Price
- $5.99
- Day Range
- $6.05–7.07
- 52-Week Range
- $5.71–11.72
- Bid/Ask
- $7.05 / $7.17
- Market Cap
- $383.91 Mil
- Volume/Avg
- 1.3 Mil / 439,191
Key Statistics
- Price/Earnings (Normalized)
- 21.80
- Price/Sales
- 2.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 162
Comparables
Valuation
|
Metric
|
VYGR
|
TSHA
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.80 | 51.55 | — |
Price/Book Value | 1.14 | 3.72 | 4.21 |
Price/Sales | 2.52 | 31.27 | — |
Price/Cash Flow | 16.05 | — | — |
Price/Earnings
VYGR
TSHA
DYN
Financial Strength
|
Metric
|
VYGR
|
TSHA
|
DYN
|
|---|---|---|---|
Quick Ratio | 9.33 | 5.05 | 26.18 |
Current Ratio | 9.51 | 5.22 | 26.63 |
Interest Coverage | — | −52.79 | — |
Quick Ratio
VYGR
TSHA
DYN
Profitability
|
Metric
|
VYGR
|
TSHA
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | 5.87% | −40.83% | −55.93% |
Return on Equity (Normalized) | 8.51% | −216.63% | −64.68% |
Return on Invested Capital (Normalized) | 2.33% | −77.31% | −63.67% |
Return on Assets
VYGR
TSHA
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Sczymltrt | Xwj | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vqtjcqgc | Prvtyv | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nwbxswnr | Btqcx | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ttvzsgxxz | Pmbfv | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Ltsjlwwcm | Grkr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Pyzpltvb | Dsbt | $29.2 Bil | |||
| Moderna Inc
MRNA
| Mtkbrgcj | Mvjh | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jntzkpv | Rjmk | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Htmdgvsnw | Xtgcn | $13.2 Bil | |||
| Incyte Corp
INCY
| Xhlyrstp | Cscqgh | $13.0 Bil |
United States